KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Deferred Taxes (2021 - 2025)

Historic Deferred Taxes for Halozyme Therapeutics (HALO) over the last 9 years, with Q3 2025 value amounting to -$27.4 million.

  • Halozyme Therapeutics' Deferred Taxes fell 926780.82% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year increase of 9164.26%. This contributed to the annual value of -$532000.0 for FY2024, which is 9845.82% up from last year.
  • Halozyme Therapeutics' Deferred Taxes amounted to -$27.4 million in Q3 2025, which was down 926780.82% from $7.1 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Deferred Taxes ranged from a high of $142.5 million in Q3 2021 and a low of -$27.4 million during Q3 2025
  • For the 5-year period, Halozyme Therapeutics' Deferred Taxes averaged around $3.7 million, with its median value being -$3.9 million (2023).
  • Examining YoY changes over the last 5 years, Halozyme Therapeutics' Deferred Taxes showed a top increase of 32137.88% in 2025 and a maximum decrease of 926780.82% in 2025.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Deferred Taxes stood at $13.0 million in 2021, then crashed by 213.3% to -$14.7 million in 2022, then skyrocketed by 35.79% to -$9.4 million in 2023, then skyrocketed by 262.28% to $15.3 million in 2024, then tumbled by 278.88% to -$27.4 million in 2025.
  • Its Deferred Taxes was -$27.4 million in Q3 2025, compared to $7.1 million in Q2 2025 and $2.9 million in Q1 2025.